Less risk

Babak S.L.

References:

Slis’ S.S., Kovalev E.V., Yanovich E.G., Kononenko A.A., Noskov A.K. The Main Risks of an Epidemic Emergency Associated with New Respiratory Viruses. Epidemiology and Vaccinal Prevention. 2022;21(2):74-82. (In Russ.) https://doi.org/10.31631/2073-3046-2022-21-2-74-82
On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2022. State report. Federal Service for Supervision of Consumer Rights Protection and Human Welfare. M.: 2023. – 368 p.
On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2023. State report. Federal Service for Supervision of Consumer Rights Protection and Human Welfare. M.: 2024. – 340 p.
World Health Organization. FluNet. Global Influenza Surveillance and Response System (GISRS). https://www.who.int/initiatives/global-influenza-surveillance-and-response-system
BIOFIRE®. Respiratory Pathogen Trends (RP2.1) [Electronic resource]. Accessed 02.12.2024. https://syndromictrends.com/
Pokrovsky V.I. Infectious diseases and epidemiology: textbook / Pokrovsky V.I., Pak S.I., Pak S. G.G., Briko N.I. – 3rd ed. revised and expanded – Moscow: GEOTAR-Media, 2016. – 1008 p.
Drapkina O.M., Kontsevaya A.V., Kalinina A.M. et al. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines. Cardiovascular Therapy and Prevention. 2024;23(3):3696. (In Russ.) https://doi.org/10.15829/1728-8800-2024-3996
Orlova N.V., Kaminer D.D. Comorbid patient with acute respiratory viral infections. Features of therapy and prevention. Medical alphabet. 2019;1(9):8-12. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-9(384)-8-12
Moffat K, Mercer SW. Challenges of managing people with multimorbidity in today’s healthcare systems. BMC Fam Pract. 2015 Oct 14;16:129. https://doi.org/10.1186/s12875-015-0344-4
GBD2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1459-1544. https://doi.org/10.1016/S0140-6736(16)31012-1
Ministry of Health of the Russian Federation. Clinical recommendations “Acute respiratory viral infections (ARVI) in adults”. [Electronic resource]. Year of approval: 2021.ID: 724. Date of circulation: 02.12.2024. https://cr.minzdrav.gov.ru/schema/724_1
Orlova NV, Lomaychikov VV. Role of etiotropic therapy in the treatment and prevention of influenza complications amidst the COVID-19 pandemic. Meditsinskiy sovet = Medical Council. 2021;(18):86-93. (In Russ.) https://doi.org/10.21518/2079-701X-2021-18-86-93
Ministry of Health of the Russian Federation. Clinical recommendations “Influenza in adults”. [Electronic resource]. Year of approval: 2022. ID: 749.Date of circulation: 02.12.2024. https://cr.minzdrav.gov.ru/schema/749_1
Instructions for medical use of the drug NOBAZIT® PRO. LP 003508 dated 31.07.2024.
Instructions for the medical use of the drug NOBASIT® FORTE. LP 006416 dated 17.08.2023.
Zarubaev V.V., Slita A.V., Sinegubova E.O.et al. Anti-viral activity of enisamium iodide against viruses of influenza and ARVI’s on different cell lines. Terapevticheskii arkhiv. - 2020;92(11):45-50. https://doi.org/10.26442/00403660.2020.11.000872
Pshenichnaya N.Yu., Zhdanov K.V., Lioznov D.A. Final results of an adaptive randomized open-label controlled study on the efficacy and safety of enisamium iodide for inpatient treatment of the COVID-19 infection. Infekc. bolezni (Infectious Diseases). 2023; 21(1): 17–24. (In Russ.) https://doi.org/10.20953/1729-9225-2023-1-17-24
Isakov V.A., Ohapkina E.A., Evgrafov V.D. Effectiveness of amizon in therapy and prevention of acute respiratory viral infections. Medical Forum. 2015;1(2):44-51.
Pshenichnaya N.Y., Bulgakova V.A., Volchkova E.V., Kareva E.N., Selkova E.P., Gorodin V.N. Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia. Terapevticheskii arkhiv. 2019;91(11):105-109. https://doi.org/10.26442/00403660.2019.11.000454
Te Velthuis AJW, Zubkova TG, Shaw M, et al. Enisamium Reduces Influenza Virus Shedding and Improves Patient Recovery by Inhibiting Viral RNA Polymerase Activity. Antimicrob Agents Chemother. 2021 Mar 18;65(4): e02605-20. https://doi.org/10.1128/AAC.02605-20
Denisova A.R., Maksimov M.L. Acute respiratory viral infections: etiology, diagnosis, modern view of treatment. RMZ. Medical Review. 2018;1(II):99-103.
Lioznov D.A., Karnaukhova E.J., Zubkova T.G., Shakhlanskaya E.V. Evaluation of the effectiveness of ARVI treatment regimen including etiotropic (enisamium iodide) and symptomatic treatment. Terapevticheskii arkhiv. 2020;92(3):50-55. https://doi.org/10.26442/00403660.2020.03.000572
Walker AP, Fan H, Keown JR, et al. Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV 2 RNA polymerases. bioRxiv [Preprint]. 2020 Jan 6:2020.04.21.053017. https://doi.org/10.1101/2020.04.21.053017
Gordienko V.V., Kozlov K.V., Shedei A.A. et al. Efficacy and safety of enisamium iodide and umifenovir in the treatment of patients with acute respiratory viral infections in real clinical practice. Treating Physician. 2024;1(27):49-55. https://doi.org/10.51793/OS.2024.27.1.007
Methodological recommendations “Diagnosis, prevention, treatment and rehabilitation of viral lung damage in SARS-CoV 2 infection”. Edited by S.N. Avdeev, A.G. Malyavin. RNMOT, 2021.
Order of the Ministry of Health of the Russian Federation from 18.03.2024 № 127n “On approval of the standard of medical care for adults with acute respiratory viral infections (ARVI) (diagnosis and treatment)”.